THDB(SH:600867)2019-10-22 16:00Financial Performance - Net profit attributable to shareholders of the listed company was CNY 688,124,696.43, representing a slight increase of 0.08% year-on-year[4] - Operating income for the first nine months was CNY 2,057,207,384.23, an increase of 2.41% compared to the same period last year[4] - The company reported a basic earnings per share of CNY 0.34, up 3.03% from the previous year[6] - The company's net profit attributable to shareholders increased to CNY 1.49 billion, up from CNY 1.21 billion in the previous year[22] - Net profit for the first three quarters of 2019 was ¥1,506,251,505.34, compared to ¥1,250,484,388.80 in the same period of 2018, reflecting a growth of 20.41%[27] - The net profit attributable to shareholders of the parent company for Q3 2019 was CNY 155.98 million, up from CNY 150.90 million in Q3 2018, representing a growth of 0.7%[30] - The total profit for Q3 2019 was CNY 181.70 million, compared to CNY 173.35 million in Q3 2018, indicating a year-over-year increase of 4.0%[32] - The company reported a total profit of CNY 800.16 million for the first three quarters of 2019, compared to CNY 799.86 million for the same period in 2018, showing a slight increase of 0.04%[32] Cash Flow - The net cash flow from operating activities increased by 32.48% year-on-year, reaching CNY 947,426,091.35[4] - Net cash flow from operating activities increased by 32.48% year-on-year, reaching approximately CNY 947.43 million[15] - Cash flow from operating activities for the first three quarters of 2019 was CNY 947.43 million, an increase from CNY 715.15 million in the same period last year, representing a growth of 32.5%[35] - The cash inflow from operating activities totaled CNY 2.08 billion in the first three quarters of 2019, compared to CNY 1.98 billion in the previous year, indicating a growth of 5.4%[35] - The net cash flow from operating activities for the first three quarters of 2019 was ¥871,643,930.49, an increase of 71.7% compared to ¥507,483,521.28 in the same period of 2018[37] - Total cash inflow from operating activities reached ¥1,957,383,084.56, up from ¥1,688,452,391.14 in the previous year, reflecting a growth of 15.9%[37] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,340,280,325.08, a decrease of 2.25% compared to the end of the previous year[4] - The company’s net assets attributable to shareholders increased by 5.95% to CNY 5,005,618,505.91 compared to the previous year[4] - Current assets totaled CNY 1.98 billion, down from CNY 2.27 billion at the end of 2018[19] - Total assets as of September 30, 2019, were ¥5,225,131,796.61, down from ¥5,350,898,326.49 at the end of 2018, a decrease of 2.34%[26] - Total liabilities decreased to ¥247,402,860.03 from ¥628,936,506.45, a decline of 60.70%[26] Research and Development - Research and development expenses increased due to the development of insulin analogs and GLP-1 receptor agonists[13] - Research and development expenses for Q3 2019 were ¥20,466,350.11, down 23.25% from ¥26,688,687.34 in Q3 2018[28] - The company's R&D expenses for Q3 2019 were CNY 19.19 million, a decrease of 23.3% from CNY 25.04 million in Q3 2018[32] Income and Expenses - Financial expenses increased by 126.94% compared to the same period last year, primarily due to increased interest expenses on bank loans[14] - Other income decreased by 92.11% year-on-year, mainly due to a reduction in government subsidies received[14] - Investment income rose by 110.99% compared to the previous year, attributed to increased long-term equity investment income accounted for using the equity method[14] - The company's operating costs for Q3 2019 were CNY 143.94 million, an increase of 29.5% from CNY 111.09 million in Q3 2018[32] - The sales expenses for Q3 2019 were CNY 214.83 million, a significant increase of 69.8% compared to CNY 126.51 million in Q3 2018[32] - The financial expenses for Q3 2019 were CNY 1.52 million, a decrease of 68.9% from CNY 4.88 million in Q3 2018[32] Government Subsidies - The company received government subsidies amounting to CNY 1,011,141.59 during the reporting period[7]